Flucyton 250 Tablet contains Flucytosine 250mg, a broad-spectrum antifungal agent used in the management of serious systemic fungal infections, including candidiasis and cryptococcosis. It works by inhibiting fungal DNA and RNA synthesis, effectively stopping the growth and spread of fungal pathogens in the body.
This tablet is particularly important in immunocompromised patients, such as those undergoing chemotherapy, organ transplants, or living with HIV/AIDS, where fungal infections can be life-threatening. Its proven efficacy and safety profile make it a trusted choice for hospital and clinical use.
Flucyton 250 belongs to the anti-infective and hospital care segment, offering high demand among hospitals, specialty clinics, and PCD pharma franchise networks. Its combination of potency and reliability ensures a competitive edge for franchise partners looking to expand in systemic antifungal therapies.
With increasing cases of systemic fungal infections and rising awareness of immunocompromised care, Flucyton 250 Tablet represents a strong B2B opportunity for pharma distributors, export markets, and institutional supply chains. This makes it a high-demand, high-margin product for any pharma portfolio.